2016 Innovation Grants - Prof. Helge Rasmussen
New therapeutic tools
Pancreatic cancers have a very poor prognosis and the project team have discovered that a protein derivative sensitises cancer cells to currently used treatments, potentially making highly treatment-resistant pancreatic cancers responsive to chemotherapy and/or radiotherapy. The augmentation treatment effect by the derivative will be examined in human pancreatic cancers expressed in mice.

Dr Helge Rasmussen, University of Sydney
Research Reports
Click to download progress reporting on the outcomes of this research.